Atea Pharmaceuticals Inc. (AVIR)
Atea Pharmaceuticals Inc. (AVIR) Stock Price, Analysis & Data
| Bid | 3.71 |
| Market Cap | 412.06M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -169.52M |
| Beta | 0.27 |
| EPS (ttm) | -2.11 |
| PE Ratio (ttm) | n/a |
| Forward PE | -3.72 |
| P/B (ttm) | 1.76 |
| P/S (ttm) | n/a |
| Earnings Date | Aug 12, 2026 |
| Ask | 6.46 |
| Volume | 169,036 |
| Avg. Volume (20D) | 359,682 |
| Open | 5.04 |
| Previous Close | 5.05 |
| Day's Range | 4.98 - 5.16 |
| 52-Week Range | 2.78 - 6.45 |
| Analyst | Buy |
| Price Target | 10 (94.17%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About AVIR
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical...
Financial Performance
In 2025, Atea Pharmaceuticals's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -158.35M, a decrease of -5.96%.
Financial StatementsAnalyst Forecast
According to 3 analyst ratings, the average rating for AVIR stock is "Buy". The 12-month stock price forecast is 10, which is upside of 94.17% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
